Mavenir has introduced its Agentic Service Assurance Framework, designed to enhance network operations through scalable, closed-loop automation using artificial intelligence. This multi-agent framework, aligned with TM Forum specifications IG1251 and IG1453, aims to accelerate autonomous network operations across multi-vendor and multi-domain environments. By capturing and automating expert workflows from Network Operations Centers (NOC), the system seeks to replicate and expand human expertise, offering solutions to challenges like fragmented operations and retiring skilled engineers. The framework integrates seamlessly with existing systems, providing cross-domain monitoring and AI-driven fault analysis to improve productivity and operational control across complex network infrastructures.

Elsewhere in the market, Shanghai Iluvatar CoreX Semiconductor was a standout up 15.3% and finishing the session at HK$726.50. Two days ago, the company was added to the FTSE All-World Index. Meanwhile, Maxone Semiconductor (Suzhou) trailed, down 5.8% to finish the session at CN¥589.89.

NVIDIA’s innovative AI-driven solutions and premium pricing prospects could be quickly transformative in the rapidly digitalizing market. Click here to explore NVIDIA’s strategic opportunities and potential risks.

On a related note, dive into our Market Insights article that discusses China’s strategic push for AI and semiconductor innovation which could benefit from the new five-year plan—get the full scoop before market dynamics shift!

Best AI Chip Stocks

• Micron Technology ended the day at $1,133.99 up 8.7%, hovering around its 52-week high.

• Advanced Micro Devices ended the day at $537.37 up 4.9%, near its 52-week high.

• NVIDIA finished trading at $210.69 up 3%.

Next Steps

• Unlock our comprehensive list of 137 AI Chip Stocks like Lattice Semiconductor, Winbond Electronics and Piotech by clicking here.

• Looking For Alternative Opportunities? AI is about to change healthcare. These 129 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.